The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study

@article{Whiskey2011TheIO,
  title={The importance of the recognition of benign ethnic neutropenia in black patients during treatment with clozapine: case reports and database study},
  author={Eromona Whiskey and Olubanke Olofinjana and David Taylor},
  journal={Journal of Psychopharmacology},
  year={2011},
  volume={25},
  pages={842 - 845}
}
Clozapine is the treatment of choice in refractory schizophrenia. Its more extensive use is limited by adverse effects and the need for regular blood monitoring. However, black patients are disadvantaged with respect to clozapine usage. Lower baseline Absolute Neutrophil Count compared with Whites leads to a greater frequency of blood testing, treatment interruptions and discontinuation. This may in part be explained by Benign Ethnic Neutropenia, but too few black patients are thus registered… 

Tables from this paper

Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals

Current evidence suggests that BEN remains an uncommonly recognised haematological phenotype, and adoption of current FDA BEN monitoring criteria in the UK may further reduce clozapine discontinuation due to perceived neutropenia as drug toxicity, particularly in treatment-refractory schizophrenia patients.

Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital

Even in this extreme group of patients with treatment resistant schizophrenia, clozapine can be safely and effectively re/initiated following neutropenias, resulting in marked benefits for patients, according to a case series of 14 consecutive patients rechallenged in a high-secure psychiatric hospital.

Clozapine Re-Challenge and Initiation Despite Neutropenia and Outcomes from 14 Patients

With careful planning and monitoring, clozapine can be successfully reinitiated following CIN or in the face of preexisting neutropenia resulting in significant benefits for patients.

Risk factors for neutropenia in clozapine-treated children and adolescents with childhood-onset schizophrenia.

The study shows that the rates of neutropenia in clozapine-treated children and adolescents are considerably higher than in the adult population.

Maximizing clozapine utilization while minimizing blood dyscrasias: evaluation of patient demographics and severity of events

Patients in the 40–49-year age range had the most events and also presented with the highest number of moderate leukopenia/granulocytopenia events as did those scheduled for weekly monitoring, whereas the majority of patients with no recorded events were female and either 20–29 or 60–69 years of age.

Changes in Neutrophil Count After Antipsychotic Prescription Among a Retrospective Cohort of Patients With Benign Neutropenia

There was a statistically significant increase in ANC among this cohort during the time of antipsychotic prescription, and all BN patients who were prescribed antipsychotics maintained a stable neutrophil count, with none of the 22 patients with BN in this study developing agranulocytosis during treatment.

Clozapine-induced agranulocytosis

A review of the epidemiology of clozapine-induced agranulocytosis (CLIA), advances in identifying genetic risk factors, and the preventive measures to reduce the risk of CLIA is presented.

Duffy-null genotype in clozapine-associated neutropenia

Background Individuals of African ancestry in the US and Europe are at increased risk of developing schizophrenia and have poorer clinical outcomes. The antipsychotic clozapine, the only licensed

Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis.

In this selected population, the initial neutropenia was unlikely to be related to clozapine in a substantial proportion of cases, and this group was successfully rechallenged following careful consideration of the risks and benefits.

References

SHOWING 1-10 OF 14 REFERENCES

Clozapine, agranulocytosis, and benign ethnic neutropenia

  • S. Rajagopal
  • Medicine, Psychology
    Postgraduate Medical Journal
  • 2005
This editorial looks at the important issues associated with agranulocytosis and BEN in patients receiving clozapine, a atypical antipsychotic effective in treatment resistant schizophrenia.

Restarting Clozapine after Neutropenia

Uncertainty over the likely cause of blood dyscrasia in people taking clozapine, coupled with uncertainty over the mechanism by which clozabine causes both neutropenia and agranulocytosis, makes any attempt to restart clozAPine a high-risk venture requiring the utmost caution.

Clozapine underutilization and discontinuation in African Americans due to leucopenia.

It is likely that African Americans had clozapine discontinued unnecessarily due to benign ethnic neutropenia, concur with recent recommendations to acknowledge differences in WBC values in African Americans and to modify prescribing guidelines or formally acknowledge benign ethnic leucopenia like in other countries.

Clozapine-induced transient white blood count disorders.

BACKGROUND The aim of the study was to shed more light on the incidence and course of clozapine-induced transient white blood count (WBC) disorders. METHOD In an analysis of our clozapine drug

Benign ethnic neutropenia: what is a normal absolute neutrophil count?

A description of benign ethnic neutropenia, as set forth in this review, suggests that the lower limit now considered acceptable for the absolute neutrophil count should be readjusted downward for all ethnic groups.

Active monitoring of 12760 clozapine recipients in the UK and Ireland

The case register yielded valuable information for guiding research into the causes of the haematological reactions in subjects receiving clozapine, and the risk for agranulocytosis in Asian subjects was 2.4 times that in Caucasians.

Circadian rhythm of white blood cells during clozapine treatment

Some patients with refractory schizophrenia may have a spuriously low cell count and may be unnecessarily denied effective treatment, as behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).

Reasons for discontinuing clozapine: matched, case-control comparison with risperidone long-acting injection.

Clozapine use in patients with severe mental illness was associated with a significantly increased risk of death compared with that for the general population andCausation could not be established.

Myocarditis and cardiomyopathy associated with clozapine

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

For patients with schizophrenia who prospectively failed to improve with an atypical antipsychotic, clozapine was more effective than switching to another newer atypicals antipsychotics.